ORGANIZATION

FPMAJ Renews Call for Changing NHI Pricing Rules for Unprofitable Drugs with Great Medical Needs

March 20, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) has compiled its action plan for FY2015 starting next month, which calls for modifying the pricing rules of unprofitable drugs with great medical needs in the next NHI price revision in…

To read the full story

Applying Uniform Pricing Rule to Unprofitable but Essential Drugs Difficult: Kenporen Veep
March 26, 2015

ORGANIZATION

Labor Union Group Submits Request, Urges Drug Pricing Overhaul amid Inflation
December 3, 2025
Wholesalers Urge Caution on Debating 2% Buffer without Bigger Reform Picture
November 28, 2025
Labor Federation Files Request for 5% Drug Price Hike with Health Minister
November 28, 2025
Japan PBSS Launches to Buttress Drug Discovery via Grassroots Networks
November 26, 2025
Labor Group Presses Lawmakers to Reflect Rising Costs in Drug Prices
November 26, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…